2016) recommended the first-line 14-day bismuth quadruple therapy (PPI, bismuth, MTZ, tetracycline (TC)) when there is above 15% CLR resistance or a concomitant therapy (PPI, AMX, MTZ, CLR), if bismuth is not available
Cagrilintide Starting Dose and Titration Unlike tirzepatide's gradual multi-step escalation, cagrilintide trials have typically employed a simpler titration approach: Typical Cagrilintide Escalation: Weeks 1-4: 0.6 mg weekly Weeks 5-8: 1.2 mg weekly Week 9 onward: 2.4 mg weekly (maintenance) This three-step approach allows for tolerance development while reaching the therapeutic dose more quickly than tirzepatide's six-step protocol
You can reduce your risk by avoiding unnecessary high doses, especially if your body does not need extra B12
Evidence level Peptide Therapy: Varies widely some peptides have early human data, others mostly experimental
L.WindhamI.MerrellD
For shoppers specifically interested in GlyNAC supplementation, the higher per-serving cost may be easier to justify because it eliminates the need to purchase NAC and glycine separately